Volume 55, Issue 3, Pages (March 2009)

Slides:



Advertisements
Similar presentations
Pascal Rischmann  European Urology Supplements 
Advertisements

The PSA Era is not Over for Prostate Cancer
Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection 
A System for Long-term Urodynamic Studies Without Catheters
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Contemporary Management of the Painful Bladder: A Systematic Review
Dae Keun Kim, Dong Won Park, Koon Ho Rha  European Urology 
Volume 61, Issue 5, Pages (May 2012)
Volume 64, Issue 4, Pages (October 2013)
Volume 50, Issue 5, Pages (November 2006)
Volume 71, Issue 4, Pages (April 2017)
Volume 60, Issue 2, Pages (August 2011)
Let the Games Begin (with EAU Approval)
Prostate Cancer Epidemic in Sight?
Volume 45, Issue 4, Pages (April 2004)
Volume 57, Issue 5, Pages (May 2010)
Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications  Anthony J. Bella, Ling X. DeYoung, Mussa al-Numi,
Volume 46, Issue 2, Pages (August 2004)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey  John B. McKinlay, Carol L. Link  European.
Volume 51, Issue 1, Pages (January 2007)
Volume 51, Issue 3, Pages (March 2007)
Volume 56, Issue 3, Pages (September 2009)
Volume 62, Issue 3, Pages (September 2012)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Prostate Cancer Detection: A View of the Future
Volume 51, Issue 2, Pages (February 2007)
Volume 64, Issue 4, Pages (October 2013)
Volume 48, Issue 4, Pages (October 2005)
Volume 60, Issue 1, Pages (July 2011)
Volume 55, Issue 3, Pages (March 2009)
Volume 72, Issue 3, Pages (September 2017)
Volume 52, Issue 4, Pages (October 2007)
Volume 49, Issue 6, Pages (June 2006)
Prostate Cancer Epidemic in Sight?
James N. Armitage, Stuart O. Irving, Neil A. Burgess  European Urology 
The PSA Era is not Over for Prostate Cancer
Volume 61, Issue 5, Pages (May 2012)
Volume 69, Issue 2, Pages (February 2016)
Volume 61, Issue 5, Pages (May 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 53, Issue 6, Pages (June 2008)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
The Inside-Out Transobturator Male Sling for the Surgical Treatment of Stress Urinary Incontinence After Radical Prostatectomy: Midterm Results of a Single-Center.
The Economic Costs of Overactive Bladder in Germany
Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl  European Urology 
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 51, Issue 1, Pages (January 2007)
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Volume 52, Issue 5, Pages (November 2007)
Volume 74, Issue 5, Pages (November 2018)
Testicular Cancer Variations in Time and Space in Europe
Volume 53, Issue 1, Pages (January 2008)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
Pharmacotherapy in Stress and Mixed Incontinence
European Urology is “Your” Journal
The Start-Up of the Platinum Journal: A Fascinating Challenge
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
Botulinum Toxin Type A Injections for Treating Neurogenic Detrusor Overactivity Combined With Low-Compliance Bladder in Patients With Spinal Cord Lesions 
Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies  David A. Ginsberg, MD, Lynne Kolton.
Economic Burden of Bladder Cancer Across the European Union
Volume 52, Issue 6, Pages (December 2007)
Volume 53, Issue 6, Pages (June 2008)
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 55, Issue 3, Pages 705-712 (March 2009) Six-Year Follow-Up of Botulinum Toxin A Intradetrusorial Injections in Patients with Refractory Neurogenic Detrusor Overactivity: Clinical and Urodynamic Results  Antonella Giannantoni, Ettore Mearini, Michele Del Zingaro, Massimo Porena  European Urology  Volume 55, Issue 3, Pages 705-712 (March 2009) DOI: 10.1016/j.eururo.2008.08.048 Copyright © 2008 Terms and Conditions

Fig. 1 Incontinence Quality of Life Questionnaire (I-QOL). European Urology 2009 55, 705-712DOI: (10.1016/j.eururo.2008.08.048) Copyright © 2008 Terms and Conditions

Fig. 2 Incontinence quality-of-life index in 17 spinal cord–injured patients with neurogenic detrusor overactivity treated with intradetrusorial botulinum toxin A: changes over 6-yr follow-up. European Urology 2009 55, 705-712DOI: (10.1016/j.eururo.2008.08.048) Copyright © 2008 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.